Update on current and potential nanoparticle cancer therapies

Current Opinion in Oncology

Volumn 25, Issue 6, 2013, Pages 646-651

  Rink, Jonathan S ^a   Plebanek, Michael P ^a,b   Tripathy, Sushant ^a,b   Thaxton, C Shad ^a,b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

chemotherapeutic; lipoprotein; nanoparticle; siRNA; targeted drug delivery

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; APTAMER; BETA SECRETASE 1; CAMPTOTHECIN; CISPLATIN; CRLX 101; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLIC ACID; GEMCITABINE; GOLD NANOPARTICLE; IRINOTECAN; IT 101; LOW DENSITY LIPOPROTEIN RECEPTOR; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; PANITUMUMAB; PREDNISONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RITUXIMAB; SCAVENGER RECEPTOR BI; SMALL INTERFERING RNA; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINCRISTINE;

BILE DUCT CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; DENDRITIC CELL; EXOSOME; GLIOMA; HUMAN; HYPOTENSION; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPHOMA; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PARTICLE SIZE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; TONSIL CANCER; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MALE; MICE; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84885432555     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000012     Document Type: Review

References (57)

1. American Cancer Society. Cancer facts & figures 2013. American Cancer Society, Inc; 2013.
2. Mestre-Ferrandiz J, Sussex J, Towse A. The R & D cost of a new medicine. London: Office of Health Economics; 2012.
3. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7:771-782.
4. Heath JR, Davis ME. Nanotechnology and cancer. Annu Rev Med 2008; 59:251-265.
5. Heidel JD, Davis ME. Clinical developments in nanotechnology for cancer therapy. Pharm Res 2011; 28:187-199.
6. Schutz CA, Juillerat-Jeanneret L, Mueller H, et al. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine 2013; 8:449-467.
7. Tanaka T, Shiramoto S, Miyashita M, et al. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism ofreceptor-mediated endocytosis (RME). Int J Pharmaceut 2004; 277:39-61.
8. Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013; 73:2412-2417.
9. Steegmann-Olmedillas JL. The role of iron in tumour cell proliferation. Clin Transl Oncol 2011; 13:71-76.
10. Wang RB, Billone PS, Mullett WM. Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J Nanomater 2013; 2013:1-12.
11. Steffensen KD, Waldstrom M, Pallisgard N, et al. Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study. Int J Gynecol Cancer 2013; 23:73-80.
12. Levine AM, Noy A, Lee JY, et al. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol 2013; 31:58-64.
13. Arrieta O, Medina LA, Estrada-Lobato E, et al. First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer 2012; 106: 1027-1032.
14. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-7803.
15. Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol 2011; 122:111-115.
16. Hosein PJ, de Lima Lopes G Jr, Pastorini VH, et al. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 2013; 36:151-156.
17. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced nonsmall-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30:2055-2062.
18. Alberts DS, Blessing JA, Landrum LM, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol 2012; 127:451-455.
19. Weiss GJ, Chao J, Neidhart JD, et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceu-tical in patients with advanced solid tumor malignancies. Invest New Drugs 2013; 31:986-1000.
20. Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 2005; 288: C975-C981.
21. Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differ entiated pharmacological profile. Sci Transl Med 2012; 4:128ra139.
22. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007; 59:75-86.
23. Davis ME. The first targeted delivery of sirna in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009; 6:659-668.
24. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464:1067-1070.
25. Eifler AC, Thaxton CS. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol Biol 2011; 726:325-338.
26. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007; 25:1149-1157.
27. Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013; 3:406-417.
28. Shenoi MM, Iltis I, Choi J, et al. Nanoparticle delivered vascular disrupting agents (VDAS): use of TNF-alpha conjugated gold nanoparticles for multi modal cancer therapy. Mol Pharm 2013; 10:1683-1694.
29. Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel pegylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010; 16:6139-6149.
30. Wiley DT, Webster P, Gale A, et al. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci USA 2013; 110:8662-8667.
31. Zheng D, Giljohann DA, Chen DL, et al. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci USA 2012; 109:11975-11980.
32. Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano 2013; 7:2078-2089.
33. Xiao Z, Levy-Nissenbaum E, Alexis F, et al. Engineering of targeted nano-particles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano 2012; 6:696-704.
34. Valencia PM, Pridgen EM, Perea B, et al. Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine 2013; 8:687-698.
35. Han H, Davis ME. Targeted nanoparticles assembled via complexation of boronic-acid-containing targeting moieties to diol-containing polymers. Bioconjug Chem 2013; 24:669-677.
36. Zhang K, Hao L, Hurst SJ, et al. Antibody-linked spherical nucleic acids for cellular targeting. J Am Chem Soc 2012; 134:16488-16491.
37. Dohmen C, Edinger D, Frohlich T, et al. Nanosized multifunctional polyplexes for receptor-mediated siRNA delivery. ACS Nano 2012; 6:5198-5208.
38. Zhao N, You J, Zeng Z, et al. An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. Small 2013. [Epub ahead of print]
39. Zhu G, Zheng J, Song E, et al. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci USA 2013; 110:7998-8003.
40. Huang S, Shao K, Liu Y, et al. Tumor-targeting and microenvironment- responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 2013; 7:2860-2871.
41. Nam J, La WG, Hwang S, et al. pH-responsive assembly of gold nanoparticles and 'spatiotemporally concerted' drug release for synergistic cancer therapy. ACS Nano 2013; 7:3388-3402.
42. Zhang HF, Wang JQ, Mao WW, et al. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies. J Control Release 2013; 166:147-158.
43. Dunn SS, Tian S, Blake S, et al. Reductively responsive siRNA-conjugated hydrogel nanoparticles for gene silencing. JAm Chem Soc 2012; 134:7423-7430.
44. Hasan W, Chu K, Gullapalli A, et al. Delivery of multiple siRNAs using lipid-coated plga nanoparticles for treatment of prostate cancer. Nano Lett 2012; 12:287-292.
45. Ren Y, Cheung HW, von Maltzhan G, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene id4. Sci Transl Med 2012; 4:112-123.
46. Lee H, Lytton-Jean AK, Chen Y, et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol 2012; 7:389-393.
47. Shahzad MMK, Mangala LS, Han HD, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011; 13:309-319.
48. Leon CG, Locke JA, Adomat HH, et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010; 70:390-400.
49. Pussinen PJ, Lindner H, Glatter O, et al. Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells. Biochem Biophys Acta 2000; 1485:129-144.
50. Damiano MG, Mutharasan RK, Tripathy S, et al. Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv Drug Deliv Rev 2013; 65:649-662.
51. Luthi AJ, Zhang H, Kim D, et al. Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS Nano 2012; 6:276-285.
52. McMahon KM, Mutharasan RK, Tripathy S, et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett 2011; 11:1208-1214.
53. Yang S, Damiano MG, Zhang H, et al. Biomimetic, synthetic HDL nano-structures for lymphoma. Proc Natl Acad Sci USA 2013; 110:2511-2516.
54. Lee JB, Zhang K, Tam YY, et al. Lipid nanoparticle sirna systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer 2012; 131:E781-E790.
55. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is anovel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9:654-659.
56. Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injectionof targeted exosomes. Nat Biotechnol 2011; 29:341-345.
57. Katakowski M, Buller B, Zheng X, et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett 2013; 335:201-204.